Antacids Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Antacids Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Oct 2017 Transparency Market Research Pharmaceutical184 Pages Price :
$ 5795

The global antacids market will clock a 3.7% CAGR between 2017 and 2025, for the market to become worth US$18.7 bn by the end of 2025.

Global Antacids Market: Scope and Methodology

This report on the global antacids market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research, conducted for understanding the arriving trends, used to forecast the expected revenue of antacids used in various gastro esophageal diseases in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each drug class, formulation type, and distribution channel. In addition, the report provides estimated market size in terms of US$ Mn for various geographic regions for the period 2015 to 2025, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering their launch date in the market, customer acceptance, volume sales, price of the product, trends in industry, end user trend, and adoption rate across all the geographies.

The market overview section of the report comprises qualitative analysis of the overall antacids market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, market opportunity analysis for the drug class, formulation type, distribution channel, and key industry developments has also been provided. Key industry developments include the major events occurred in past 4-5 years and are expected to occur during the forecast period which are likely to affect the market dynamics.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, formulation type, distribution channel, and geography. The report also provides value chain analysis of the market that describes the sequence of activities involved, from identification of the market need to their final reach to the end users. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market.

Global Antacids Market: Segmentation

Antacids can be defined as medicines used to suppress the acid production in stomach. They fall in different drug class depending on their mechanism of action.

Based on drug class, global antacids market is segmented into proton pump inhibitor (PPI), H2 antagonists and acid neutralizers. Proton pump inhibitor are strong and effective drugs, used to inhibit the acid production. They are mainly used to treat gastro esophageal reflux diseases (GERD), peptic ulcers, etc. These drugs are often used for occasional heartburn, acidity, upset stomach, acid indigestion etc. This report analyzes the current and future prospects of the antacids market based on drug class, formulation type, distribution channel, and geography.  

Based on formulation type, the market is segmented into tablets, liquid, powder and others. The others segment which include melt in mouth granules, disintegrating thin films, gummies, etc. is likely to have steady growth during the forecast period, while tablets segment is projected to account for dominant share of global antacids market. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and others. Retail pharmacies segment is anticipated to hold significant share and have steady growth during the forecast period. Others segment which include online pharmacies and drug stores is projected to account for dominating share in global antacids market.

Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

Migraine Drugs Market: Geographical and Competitive Dynamics

The report concludes with the profiles of major players in the global gastrointestinal drugs market such as AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Reckitt Benckiser Group plc, Sanofi, Sun Pharmaceuticals Ltd., Takeda Pharmaceutical, Valeant Pharmaceuticals International, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global antacids market has been segmented as follows:

  • Global antacids Market, by Drug Class
    • Proton pump inhibitors
    • H2 Antagonist
    • Acid neutralizers
       
  • Global antacids Market, by Formulation Type
    • Tablet
    • Liquid
    • Powder
    • Others
  • Global antacids Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others  
       
  • Global antacids Market, by Region 
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • France
      • Germany
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • Saudi Arabia
      • South Africa
      • Rest of Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Antacids Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Antacids Market Value (US$ Mn) Forecast, 2017 - 2025
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
4.7. Market Outlook

5. Global Antacids Market Analysis and Forecasts, By Drug Class 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
5.4.1. Proton pump inhibitors
5.4.2. H2 Antagonist
5.4.3. Acid neutralizers
5.5. Market Attractiveness By Drug Class 

6. Global Antacids Market Analysis and Forecasts, By Formulation Type 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
6.4.1. Tablet
6.4.2. Liquid
6.4.3. Powder
6.4.4. Others
6.5. Market Attractiveness By Formulation Type 

7. Global Antacids Market Analysis and Forecasts, By Distribution Channel 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends 
7.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Others
7.5. Market Attractiveness By Distribution Channel 

8. Global Antacids Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value (US$ Mn) Forecast, By Region, 2017-2025
8.2.1. North America 
8.2.2. Europe 
8.2.3. Asia Pacific 
8.2.4. Latin America 
8.2.5. Middle East and Africa 
8.3. Market Attractiveness By Region

9. North America Antacids Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
9.2.1. Proton pump inhibitors
9.2.2. H2 Antagonist
9.2.3. Acid neutralizers
9.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
9.3.1. Tablet
9.3.2. Liquid
9.3.3. Powder
9.3.4. Others
9.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Others
9.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis 
9.6.1. By Drug Class 
9.6.2. By Formulation Type 
9.6.3. By Distribution Channel 
9.6.4. By Country

10. Europe Antacids Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
10.2.1. Proton pump inhibitors
10.2.2. H2 Antagonist
10.2.3. Acid neutralizers
10.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
10.3.1. Tablet
10.3.2. Liquid
10.3.3. Powder
10.3.4. Others
10.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
10.5.1. U.K.
10.5.2. Germany
10.5.3. France 
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis 
10.6.1. By Drug Class 
10.6.2. By Formulation Type 
10.6.3. By Distribution Channel 
10.6.4. By Country

11. Asia Pacific Antacids Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
11.2.1. Proton pump inhibitors
11.2.2. H2 Antagonist
11.2.3. Acid neutralizers
11.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
11.3.1. Tablet
11.3.2. Liquid
11.3.3. Powder
11.3.4. Others
11.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
11.5.1. India 
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand 
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis 
11.6.1. By Drug Class 
11.6.2. By Formulation Type 
11.6.3. By Distribution Channel 
11.6.4. By Country

12. Latin America Antacids Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
12.2.1. Proton pump inhibitors
12.2.2. H2 Antagonist
12.2.3. Acid neutralizers
12.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
12.3.1. Tablet
12.3.2. Liquid
12.3.3. Powder
12.3.4. Others
12.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
12.5.1. Brazil 
12.5.2. Mexico 
12.5.3. Rest of Latin America 
12.6. Market Attractiveness Analysis 
12.6.1. By Drug Class 
12.6.2. By Formulation Type 
12.6.3. By Distribution Channel 
12.6.4. By Country

13. Middle East and Africa Antacids Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Key Trends
13.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
13.2.1. Proton pump inhibitors
13.2.2. H2 Antagonist
13.2.3. Acid neutralizers
13.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
13.3.1. Tablet
13.3.2. Liquid
13.3.3. Powder
13.3.4. Others
13.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
13.5.1. South Africa 
13.5.2. Saudi Arabia 
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis 
13.6.1. By Drug Class 
13.6.2. By Formulation Type 
13.6.3. By Distribution Channel 
13.6.4. By Country

14. Competition Landscape
14.1. Market Players
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. AstraZeneca
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Business Overview
14.2.1.3. Product Portfolio 
14.2.1.4. Financial Overview 
14.2.1.5. SWOT Analysis 
14.2.1.6. Strategic overview
14.2.2. Bayer AG 
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Business Overview
14.2.2.3. Product Portfolio 
14.2.2.4. Financial Overview 
14.2.2.5. SWOT Analysis 
14.2.2.6. Strategic overview
14.2.3. Boehringer Ingelheim GmbH
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Business Overview
14.2.3.3. Product Portfolio 
14.2.3.4. Financial Overview 
14.2.3.5. SWOT Analysis 
14.2.3.6. Strategic overview 
14.2.4. Dr. Reddy’s Laboratories Ltd.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Business Overview
14.2.4.3. Product Portfolio 
14.2.4.4. Financial Overview 
14.2.4.5. SWOT Analysis 
14.2.4.6. Strategic overview
14.2.5. GlaxoSmithKline plc
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Business Overview
14.2.5.3. Product Portfolio 
14.2.5.4. Financial Overview 
14.2.5.5. SWOT Analysis 
14.2.5.6. Strategic overview
14.2.6. Johnson & Johnson
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Business Overview
14.2.6.3. Product Portfolio 
14.2.6.4. Financial Overview 
14.2.6.5. SWOT Analysis 
14.2.6.6. Strategic overview 
14.2.7. Pfizer Inc. 
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Business Overview
14.2.7.3. Product Portfolio 
14.2.7.4. Financial Overview 
14.2.7.5. SWOT Analysis 
14.2.7.6. Strategic overview
14.2.8. Procter & Gamble
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Business Overview
14.2.8.3. Product Portfolio 
14.2.8.4. Financial Overview 
14.2.8.5. SWOT Analysis 
14.2.8.6. Strategic overview
14.2.9. Reckitt Benckiser Group plc
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Business Overview
14.2.9.3. Product Portfolio 
14.2.9.4. Financial Overview 
14.2.9.5. SWOT Analysis 
14.2.9.6. Strategic overview
14.2.10. Sanofi
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Business Overview
14.2.10.3. Product Portfolio 
14.2.10.4. Financial Overview 
14.2.10.5. SWOT Analysis 
14.2.10.6. Strategic overview
14.2.11. Sun Pharmaceuticals Ltd
14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.11.2. Business Overview
14.2.11.3. Product Portfolio 
14.2.11.4. Financial Overview 
14.2.11.5. SWOT Analysis 
14.2.11.6. Strategic overview 
14.2.12. Takeda Pharmaceutical
14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.12.2. Business Overview
14.2.12.3. Product Portfolio 
14.2.12.4. Financial Overview 
14.2.12.5. SWOT Analysis 
14.2.12.6. Strategic overview
14.2.13. Valeant Pharmaceuticals International, Inc.
14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.13.2. Business Overview
14.2.13.3. Product Portfolio 
14.2.13.4. Financial Overview 
14.2.13.5. SWOT Analysis 
14.2.13.6. Strategic overview

List of Table

Table 01: Global Antacids Market Size (US$ Mn) Forecast, By Drug Class, 2015–2025
Table 02: Global Antacids Market Size (US$ Mn) Forecast, By Formulation Type, 2017–2025
Table 03: Global Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 04: Global Antacids Market (US$ Mn) Forecast, By Region, 2015–2025
Table 05: North America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 06: North America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 07: North America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 08: North America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 09: Europe Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 10: Europe Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 11: Europe Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 12: Europe Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 13: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 14: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 15: Asia Pacific Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 16: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Latin America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 18: Latin America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 19: Latin America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 20: Latin America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 21: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 22: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 23: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 24: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025

List of Chart

Figure 01: Global Antacids Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, By Drug Class (2016)
Figure 03: Market Value Share, By Formulation Type (2016)
Figure 04: Market Value Share By, Distribution Channel (2016)
Figure 05: Market Value Share, By Region (2016)
Figure 06: Porter’s Five Force Analysis
Figure 07: Global Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 08: Global Proton Pump Inhibitor Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 09: Global H2 Antagonist Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global Acid Neutralizer Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Antacids Market Attractiveness Analysis, By Drug Class
Figure 12: Global Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 13: Global Antacids Tablet Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Antacids Liquids Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Antacids Powder Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 17: Global Antacids Market Attractiveness Analysis, By Formulation Type
Figure 18: Global Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 19: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 20: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 21: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 22: Global Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 23: Global Antacids Market Value Share, By Region, 2017 and 2025
Figure 24: Global Antacids Market Attractiveness Analysis, By Region Type
Figure 25: North America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 26: North America Antacids Market Attractiveness Analysis, By Country
Figure 27: North America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 28: North America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 29: North America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 30: North America Market Value Share Analysis, By Country, 2016 and 2025
Figure 31: North America Antacids Market Attractiveness Analysis, By Drug Class
Figure 32: North America Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 33: North America Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 34: Europe Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 35: Europe Antacids Market Attractiveness Analysis, By Country
Figure 36: Europe Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 37: Europe Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 38: Europe Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 39: Europe Market Value Share Analysis, By Country, 2016 and 2025
Figure 40: Europe Antacids Market Attractiveness Analysis, By Drug Class
Figure 41: Europe Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 42: Europe Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 43: Asia Pacific Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 44: Asia Pacific Antacids Market Attractiveness Analysis, By Country
Figure 45: Asia Pacific Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 46: Asia Pacific Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 47: Asia Pacific Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 48: Asia Pacific Market Value Share Analysis, By Country, 2016 and 2024
Figure 49: Asia Pacific Antacids Market Attractiveness Analysis, By Drug Class
Figure 50: Asia Pacific Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 51: Asia Pacific Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 52: Latin America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 53: Latin America Antacids Market Attractiveness Analysis, By Country
Figure 54: Latin America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 55: Latin America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 56: Latin America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 57: Latin America Market Value Share Analysis, By Country, 2016 and 2024
Figure 58: Latin America Antacids Market Attractiveness Analysis, By Drug Class
Figure 59: Latin America Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 60: Latin America Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 61: Middle East and Africa Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 62: Middle East and Africa Antacids Market Attractiveness Analysis, By Country
Figure 63: Middle East and Africa Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 64: Middle East and Africa Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 65: Middle East and Africa Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 66: Middle East and Africa Market Value Share Analysis, By Country, 2016 and 2025
Figure 67: Middle East and Africa Antacids Market Attractiveness Analysis, By Drug Class
Figure 68: Middle East and Africa Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 69: Middle East and Africa Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 70: AstraZeneca, Breakdown of Net Sales (%), by Region, 2016
Figure 71: AstraZeneca, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 72: Bayer AG, Breakdown of Net Sales (%), by Region, 2016
Figure 73: Bayer AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 74: Boehringer Ingelheim, Break down of Net Sales (%), by Region, 2016
Figure 75: Boehringer Ingelheim, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 76: Dr. Reddy’s, Breakdown of Net Sales (%), by Region, 2016
Figure 77: Dr. Reddy’s, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 78: GlaxoSmithKline, Breakdown of Net Sales (%), by Region, 2016
Figure 79: GlaxoSmithKline, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 80: Johnson & Johnson, Break down of Net Sales (%), by Region, 2016
Figure 81: Johnson & Johnson, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
Figure 82: Pfizer Inc., Breakdown of Net Sales (%), by Region, 2016 (%)
Figure 83: Pfizer Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 84: P&G, Breakdown of Net Sales (%), by Region, 2016
Figure 85: P&G, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 86: Reckitt Benckiser, Breakdown of Net Sales (%), by Region, 2016
Figure 87: Reckitt Benckiser, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 88: Sanofi, Breakdown of Net Sales (%), by Region, 2016
Figure 89: Sanofi, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 90: Breakdown of Net Sales (%), by Region, 2016
Figure 91: Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 92: Takeda Pharmaceutical, Break down of Net Sales (%), by Region, 2016
Figure 93: Takeda Pharmaceutical, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 94: Valeant Pharmaceuticals International, Inc., Break down of Net Sales (%), by Region, 2016
Figure 95: Valeant Pharmaceuticals International, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top